Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Kandimalla, Ramesha; b; * | Reddy, P. Hemachandraa; b; c; d; e; *
Affiliations: [a] Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX, USA | [b] Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA | [c] Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA | [d] Departments of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA | [e] Garrison Institute on Aging, South West Campus, Texas Tech University Health Sciences Center, Lubbock, TX, USA
Correspondence: [*] Correspondence to: Ramesh Kandimalla, PhD, Research Assistant Professor, Garrison Institute on Aging and Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9424/4A 124, Lubbock, TX 79430, USA. E-mail: ramesh.kandimalla@ttuhsc.edu and P. Hemachandra Reddy, PhD, Executive Director and Chief Scientific Officer, Mildred and Shirley L. Garrison Chair in Aging, Professor of Cell Biology and Biochemistry, Departments of Neuroscience/Pharmacology and Neurology, Texas Tech University Health Sciences Center, 3601 4th Street, MS/9424/4A 124, Lubbock, TX 79430, USA. Tel.: +1 806 743 2385; Fax: +1 806 743 3636; E-mail: hemachandra.reddy@ttuhsc.edu.
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by the loss of memory, multiple cognitive impairments and changes in the personality and behavior. Several decades of intense research have revealed that multiple cellular changes are involved in disease process, including synaptic damage, mitochondrial abnormalities and inflammatory responses, in addition to formation and accumulation of amyloid-β (Aβ) and phosphorylated tau. Although tremendous progress has been made in understanding the impact of neurotransmitters in the progression and pathogenesis of AD, we still do not have a drug molecule associated with neurotransmitter(s) that can delay disease process in elderly individuals and/or restore cognitive functions in AD patients. The purpose of our article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD. We also updated the current status of clinical trials using neurotransmitters’ agonists/antagonists in AD.
Keywords: Acetylcholine inhibitors, adenosine receptors, Alzheimer’s disease, histaminergic, N-methyl-D-aspartate, neurotransmitters
DOI: 10.3233/JAD-161118
Journal: Journal of Alzheimer's Disease, vol. 57, no. 4, pp. 1049-1069, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl